Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Documenti analoghi

• Superior GVHD ‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
  di: Yishan Ye, et al.
  Pubblicazione: (2025)
• Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study
  di: Justin Loke, et al.
  Pubblicazione: (2024)
• Improved post‐transplant outcomes since 2000 for Ph‐positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party
  di: Ali Bazarbachi, et al.
  Pubblicazione: (2025)
• Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia
  di: Marion Larue, et al.
  Pubblicazione: (2024)
• Graft‐versus‐host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post‐transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation
  di: Avichai Shimoni, et al.
  Pubblicazione: (2025)